Clinical trials: Dry Eye Syndromes
Dry Eye Syndrome
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT02974907
- Testing
- RGN-259
- Where
- 10 sites in United States
- Volunteers
- 601 people
- Sponsor
- ReGenTree, LLC
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Dry Eye Disease
Safety Study of Tivanisiran to Treat Dry Eye
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
- Trial name
- FYDES (NCT05310422)
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 25 sites in United States
- Volunteers
- 301 people
- Sponsor
- Sylentis, S.A.
Dry Eye Syndromes, Dry Eye
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- ARISE-3 (NCT03937882)
- Testing
- RGN-259
- Where
- 20 sites in United States
- Volunteers
- 700 people
- Sponsor
- ReGenTree, LLC
Dry Eye Disease, Endothelial Cell
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
- Trial name
- NCT06329661
- Testing
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Novaliq GmbH
Dry Eye, Insulin Sensitivity
Topical Insulin for Ocular Surface Interface in Dry Eye Disease
This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease.
- Trial name
- NCT06939959
- Testing
- Artificial tear, insulin human
- Where
- Pakistan
- Volunteers
- 128 people
- Sponsor
- Khyber Teaching Hospital
Dry Eye
A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy
- Trial name
- NCT06346340
- Testing
- Miebo
- Where
- 12 sites in United States
- Volunteers
- 97 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconus, Dry Eye
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
Drug delivery platforms are an innovative exciting advancement in ophthalmology. They allow patients to eliminate topical medications which are generally associated with lack of compliance, difficulty of use and requiring help…
- Conditions
- Keratoconus, Dry Eye, Allergy
- Trial name
- NCT04418999
- Testing
- dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Illinois College of Optometry
Dry Eye, Graft-versus-host-disease
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye…
- Conditions
- Dry Eye, Graft-versus-host-disease, Ocular Discomfort
- Trial name
- NCT03414645
- Testing
- CAM-101 10%, Vehicle Control, CAM-101 30%
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cambium Bio Limited
Eye Pain
Pilot Study of TENS for Ocular Pain
Approximately 20% of Veterans have a diagnosis of dry eye (DE) syndrome which is often accompanied by ocular pain that significantly impacts activities of daily living.
- Trial name
- NCT05531643
- Testing
- High frequency forehead TENS, Low frequency forehead TENS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Office of Research and Development
Dry Eye Disease, Meibomian Gland Dysfunction
Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.
- Conditions
- Dry Eye Disease, Meibomian Gland Dysfunction, Cataract Senile, Dry Eye Syndromes
- Trial name
- NCT06483750
- Testing
- Systane iLux Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- George Washington University
Dry Eye Syndrome
Safety and Efficacy of BRM421 for Dry Eye Syndrome
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT03066219
- Testing
- BRM421
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- BRIM Biotechnology Inc.
Dry Eye Syndrome
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT04343287
- Testing
- BRM421
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- BRIM Biotechnology Inc.
Dry Eye Disease
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
- Trial name
- NCT06544694
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial Tears
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).
- Trial name
- NCT06660290
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial tears
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Dry Eye
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire.
- Trial name
- PRO-037 (NCT04704531)
- Testing
- Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day
- Where
- Mexico
- Volunteers
- 141 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in…
- Trial name
- PRO-087 (NCT04702776)
- Testing
- Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%, Sodium hyaluronate 0.15%, Sodium hyaluronate 0.4%
- Where
- Mexico
- Volunteers
- 182 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease
Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
The purpose of this study is to evaluate and demonstrate the efficacy and safety of an investigational ocular lubricant formulation in patients with mild to moderate dry eye disease (DED).
- Trial name
- NCT06444516
- Testing
- FID123300 ocular lubricant
- Where
- 9 sites in United States
- Volunteers
- 188 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Disease
IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.
- Trial name
- NCT06400459
- Testing
- IVW-1001 Ophthalmic Eyelid Wipe 0.1%, IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- IVIEW Therapeutics Inc.